Table 2.
Odds ratios (OR) and 95% CIs for the association between variants in ATIC, SHMT2, and SLC46A1and ovarian carcinoma stratified by multivitamin supplement use among 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University.
| Gene/SNP rsID | Multivitamin non-users |
Multivitamin usersa |
Pintc | FDRd | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Homozygous major allele (referent) | Heterozygous | Homozygous minor allele | Ordinal (per minor allele) | Homozygous major allele (referent) | Heterozygous | Homozygous minor allele | Ordinal (per minor allele) | |||
| Cases/controls | Cases/controls | Cases/controls | OR (95%CI)b | Cases/controls | Cases/controls | Cases/controls | OR (95%CI)b | |||
| ATIC | ||||||||||
| rs3772078 | 212/319 | 95/160 | 6/14 | 0.9 (0.7–1.2) | 122/241 | 58/110 | 7/16 | 1.0 (0.7–1.4) | 0.54 | 0.63 |
| rs2372536 | 137/225 | 156/226 | 28/55 | 1.0 (0.8–1.2) | 98/167 | 64/162 | 25/44 | 0.9 (0.7–1.2) | 0.52 | 0.63 |
| rs1880586 | 76/131 | 176/268 | 71/108 | 1.1 (0.9–1.3) | 52/107 | 84/188 | 51/83 | 1.1 (0.9–1.4) | 0.79 | 0.79 |
| rs1983462 | 147/235 | 146/221 | 31/51 | 1.0 (0.8–1.3) | 97/166 | 73/180 | 18/32 | 0.8 (0.6–1.1) | 0.27 | 0.45 |
| rs16853826 | 258/378 | 65/122 | 1/7 | 0.7 (0.5–1.0) | 139/291 | 46/80 | 3/7 | 1.2 (0.8–1.7) | 0.09 | 0.23 |
| rs7586969 | 115/199 | 161/235 | 47/72 | 1.1 (0.9–1.4) | 81/135 | 83/185 | 24/58 | 0.8 (0.6–1.0) | 0.07 | 0.23 |
| rs16853834 | 227/356 | 85/140 | 12/11 | 1.0 (0.8–1.4) | 119/281 | 60/87 | 9/10 | 1.5 (1.1–2.1) | 0.07 | 0.23 |
| rs1404772 | 279/450 | 43/55 | 2/2 | 1.3 (0.9–1.9) | 167/325 | 20/51 | 1/2 | 0.8 (0.5–1.3) | 0.17 | 0.31 |
| rs7604984 | 106/189 | 172/241 | 46/77 | 1.1 (0.9–1.3) | 81/128 | 77/187 | 30/62 | 0.8 (0.6–1.1) | 0.12 | 0.26 |
| SHMT2 | ||||||||||
| rs7301155e | 46/76 | 48/101 | 16/25 | 1.0 (0.7–1.4) | 23/104 | 42/93 | 8/20 | 1.7 (1.1–2.6) | 0.08 | 0.23 |
| rs2229716 | 300/462 | 23/44 | 1/1 | 0.8 (0.5–1.4) | 174/348 | 14/29 | 0/0 | 0.9 (0.5–1.9) | 0.70 | 0.75 |
| SLC46A1 | ||||||||||
| rs9894260 | 265/419 | 57/86 | 1/2 | 1.0 (0.7–1.4) | 151/319 | 32/58 | 4/1 | 1.5 (1.0–2.3) | 0.08 | 0.23 |
| rs739439 | 216/350 | 93/148 | 14/9 | 1.2 (0.9–1.5) | 126/237 | 56/124 | 5/17 | 0.8 (0.6–1.1) | 0.09 | 0.23 |
| rs2239908 | 98/159 | 163/253 | 62/94 | 1.0 (0.8–1.3) | 57/102 | 96/203 | 34/72 | 0.9 (0.7–1.2) | 0.54 | 0.63 |
| rs17719944 | 270/426 | 50/75 | 4/6 | 1.0 (0.7–1.5) | 152/298 | 34/77 | 1/3 | 0.9 (0.6–1.3) | 0.46 | 0.63 |
aAt least 4 pills per week during the previous year for at least 48 months’ duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects).
bAdjusted for age (<40, 40–49, 50–59, 60–69, and 70+ years), region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota, South Dakota, and North Carolina), body mass index, age at menarche, oral contraceptive use, postmenopausal status, postmenopausal hormone use, parity/age at first birth, smoking, and education (see Table 1 for categories). SNP effect was determined using a log-additive logistic regression model.
cP for interaction.
dFalse discovery rate q-value.
eMayo Clinic subjects only.